The published record on Thymosin Beta-4 and the seven-amino-acid fragment.

What the record contains

The research on this page is almost entirely about the full 43-amino-acid Thymosin Beta-4 protein, not the seven-amino-acid TB-500 fragment. The distinction matters: every registered human trial has used the parent protein. The TB-500 fragment appears in equine doping-control detection work and a handful of cell and animal studies, but its human pharmacology is uncharted. What follows is the published record on how Thymosin Beta-4 works — actin sequestration, angiogenesis, cardiac signaling, corneal repair, brain injury — organized by tissue system and citation, with the fragment-versus-parent distinction preserved throughout.

The molecule

Thymosin Beta-4 is a 43-amino-acid intracellular peptide encoded by the X-linked TMSB4X gene and conserved across nearly every eukaryotic lineage examined. It is expressed in essentially every nucleated cell type, with particularly high levels in platelets, macrophages, and polymorphonuclear cells. The central biological role is G-actin sequestration: each Tβ4 molecule binds one monomeric actin unit through a flexible structure organized around the central LKKTET motif, regulating the cellular pool of polymerization-ready actin ^[4].

TB-500 — the synthetic peptide marketed under that name — is the heptapeptide Ac-LKKTETQ-OH, corresponding to residues 17–23 of the parent protein. Molecular formula C37H67N9O14; CAS 885340-08-9; monoisotopic mass approximately 889.5 Da. N-terminal acetylation blocks aminopeptidase cleavage and improves solution stability. The fragment carries the LKKTET motif but lacks the C-terminal α-helix that crystallographic work has identified as the principal structural determinant of high-affinity actin sequestration in the parent peptide ^[22].

The pharmacological consequence of that structural difference is the unresolved question at the center of the entire TB-500 literature. Vendor materials treat the fragment and the parent as functionally equivalent. The published comparison studies that would settle the matter have not been done.

Angiogenesis: HIF-1α, VEGF, and Notch

Among the best-characterized downstream effects of full-length Tβ4 is its induction of vascular endothelial growth factor. In human umbilical vein endothelial cells exposed to recombinant Tβ4 at 10–100 ng/mL, Jo and colleagues found that the peptide stabilized HIF-1α protein under both normoxic and hypoxic conditions, leading to increased VEGF transcription and secretion. HIF-1α siRNA abolished the effect ^[1].

The loop runs in both directions. Ryu and colleagues found that nitric oxide regulates Tβ4 expression through HIF-1α binding to the Tβ4 promoter, identifying the peptide itself as a hypoxia-responsive gene ^[2]. The result is a positive feedback circuit in which hypoxic stress raises Tβ4 expression, and Tβ4 in turn stabilizes HIF-1α to drive angiogenesis.

A further step is Notch signaling. Kim and Kwon showed that inhibition of either Notch1 or Notch4 receptors blocked Tβ4-induced VEGF and HIF-1α expression in HUVEC cells and abolished tube formation in subcutaneous Matrigel plugs containing 1 μg Tβ4 ^[3]. Notch is obligate downstream of Tβ4 for angiogenic activity, not merely correlated with it.

Anti-inflammation and the AcSDKP axis

Beyond actin sequestration and angiogenesis, Tβ4 directly modulates inflammatory transcription. Qiu and colleagues found that recombinant Tβ4 bound NF-κB RelA/p65 in human HCT116 and HeLa cells, blocking TNF-α-driven NF-κB transactivation and downstream IL-8 transcription. The integrin-linked-kinase partner PINCH-1 sensitized the effect ^[4].

A distinct anti-inflammatory and antifibrotic effect operates through proteolytic cleavage. The N-terminal tetrapeptide AcSDKP — N-acetyl-Ser-Asp-Lys-Pro, also called Goralatide — is released from Tβ4 by meprin and prolyl oligopeptidase and carries its own antifibrotic and pro-angiogenic activity. A 2019 review in the Canadian Journal of Physiology and Pharmacology catalogued the Tβ4–AcSDKP pathway across arteries, heart, lungs, and kidneys as the dominant mechanistic frame for Tβ4's cardiovascular and renal effects ^[19].

Purinergic signaling adds another layer in epithelial repair contexts. Yang and colleagues found that Tβ4 promoted human corneal epithelial cell migration through increased extracellular ATP release, P2X7 receptor-mediated calcium influx, and ERK1/2 activation. P2X7 antagonists blocked the migration effect ^[5].

Tissue repair: cornea, dermis, brain, heart

The seminal preclinical work on Tβ4 in corneal repair is Sosne and colleagues' 2002 alkali-burn mouse study, in which topical Tβ4 at 5 μg in 5 μL PBS, twice daily, accelerated corneal re-epithelialization at all observed time points and reduced IL-1β, KC, and MIP-2 inflammatory chemokine mRNA ^[6]. The study underwrites the entire RGN-259 ophthalmic clinical program. A 2024 paper from the same laboratory extended the work to engineered tandem-repeat constructs containing two LKKTET actin-binding motifs, which accelerated corneal closure and restored a thicker continuous epithelial architecture in rat alkali-injury models — evidence that short LKKTET-containing constructs preserve the parent peptide's corneal activity ^[16].

In the central nervous system, Xiong and colleagues administered Tβ4 intraperitoneally at 6 mg/kg or 30 mg/kg starting six hours after controlled cortical-impact traumatic brain injury in adult male Wistar rats. The intervention increased dentate gyrus neurogenesis 4.5-fold and 5.6-fold respectively over baseline and improved sensorimotor and spatial-learning outcomes ^[7]. Morris and colleagues administered Tβ4 intravenously at 3.75 mg/kg 24 hours after embolic middle-cerebral-artery occlusion in rats, improving adhesive-removal and modified Neurological Severity Score from day 14 to day 56 ^[8].

In the heart, Smart and colleagues found that Tβ4 mobilized adult epicardial progenitor cells in mice, restored their multipotent capacity, and drove neovascularization after coronary ligation ^[9]. Bock-Marquette and colleagues identified the PINCH–ILK–Akt complex as the cardiomyocyte survival mechanism: in coronary-ligation MI mice, Tβ4 reduced scar tissue and improved fractional shortening at four weeks ^[10].

The negative result and the context-dependence

Not every preclinical model has replicated. Wei and colleagues administered Tβ4 systemically (150 μg/kg IV bolus plus maintenance) in a closed-chest porcine 90-minute ischemia / 24-hour reperfusion model, before and after ischemia, and found no reduction in infarct size by TTC or MRI at 24 hours ^[11]. The pig result is the clearest published counterpoint to the rodent cardiac data and the most-cited example of the rodent-to-large-mammal translation gap that shapes the present clinical-development landscape.

The context-dependence runs in another direction in the liver. Lee and colleagues, working with a hepatic-stellate-cell conditional knockout in a CCl4 mouse fibrosis model, found that loss of Tβ4 reduced αSMA-positive activated stellate cells and ameliorated fibrotic scarring — Tβ4 is pro-fibrotic in that cell type, mediated through Hedgehog signaling, in apparent contrast to its broadly antifibrotic action via AcSDKP elsewhere ^[18]. Indiscriminate systemic dosing is not biologically neutral.

Human clinical evidence

Two published Phase I trials have established human safety for intravenous recombinant Tβ4. Ruff and colleagues administered single doses of 42, 140, 420, and 1,260 mg intravenously, then a multiple-dose extension, to 40 healthy adult volunteers in a randomized, double-blind, placebo-controlled US trial. No dose-limiting toxicities and no serious adverse events were reported; adverse events were mild to moderate only ^[12]. Wang and colleagues' Chinese first-in-human trial of recombinant Tβ4 (NL005) in 84 healthy volunteers — single doses 0.05–25 μg/kg IV, multiple-dose 0.5–5 μg/kg/day × 10 — reported dose-proportional pharmacokinetics, no SAEs, and favorable immunogenicity ^[23].

The most-developed efficacy program is ophthalmic. The Phase III neurotrophic-keratopathy trial NCT02600429 in 18 patients found complete corneal healing at day 29 in 60% of 0.1% RGN-259-treated subjects vs 12.5% of placebo (p=0.066), with statistically significant healing at day 43 (p=0.036) and a sustained effect after washout ^[14]. Subsequent Phase III ophthalmic trials missed their primary endpoints: ARISE-3 in dry eye and SEER-3 in European neurotrophic keratitis. The Phase IIb cardiac trial NCT05984134 enrolled 90 acute-MI patients post-PCI to receive recombinant Tβ4 0.5 μg/kg or 1.0 μg/kg or placebo IV within 12 hours, then on days 2–7; cardiac MRI infarct size and microvascular obstruction at day 5 and day 90 were the primary endpoints. Primary completion was May 2023; results have not yet been published ^[13].

The synthetic seven-amino-acid TB-500 fragment has never been evaluated in a registered human clinical trial. The detection record exists — Esposito and colleagues validated a liquid chromatography–mass spectrometry method for TB-500 in equine urine and plasma after intravenous administration, the method now in routine use by horse-racing authorities ^[15] — but a detection method is not a pharmacokinetic or efficacy study.

The 2024–2025 direction of travel

Recent work has moved away from free-peptide systemic dosing and toward combination biomaterial delivery. Yu and colleagues, in 2025, formulated an adipose-stem-cell exosome-loaded hemostatic and antibacterial HAMA/PLMA dual-photopolymerizable hydrogel overexpressing Tβ4. In streptozotocin-induced type-1 diabetic mice, the hydrogel accelerated full-thickness wound closure, increased CD31-positive neovascularization, and shifted macrophage polarization through PI3K/AKT/mTOR/HIF-1α activation ^[17]. The engineered-tandem-peptide and Tβ4-selenium combination work in 2024–2025 reinforces the direction: the peptide is increasingly studied as an active component of a delivery construct rather than as a standalone therapeutic ^[16].

A Frontiers in Endocrinology comprehensive review in 2021 catalogued Tβ4's roles across cardiovascular, neural, ocular, and hepatic systems and remains the standard reference for the clinical-translation status of the full-length molecule ^[24].